… Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-… lung cancer
(NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung …

… Here, we describe the activity of afatinib in patients with uncommon EGFR mutations in the
LUX-Lung clinical trials programme, with data from the non-randomised phase 2 LUX-Lung 2 …

… patients with clinically acquired resistance to gefitinib or erlotinib. On the other hand, the
LUX-Lung 2 trial shows that afatinib is highly active in the EGFR-mutant subgroup of patients. …

… (LUX-Lung 2) was initiated to further assess the efficacy of afatinib in lung adenocarcinoma
patients … , stage 3B/4 lung adenocarcinoma patients were treated with afatinib 40 or 50 mg …

… of the lung harboring EGFR mutations, and will assess the efficacy of afatinib versus … This
study will comprise 330 patients; these patients will either receive 40-mg afatinib daily or a …

… We aimed to assess the effect of afatinib on overall survival of patients with EGFR
mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …

… with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone
in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy. Patients and …

… of patients in both treatment groups had tumour shrinkage, with a higher proportion of afatinib
patients … The proportion of patients achieving an objective responses according to EGFR …

… of patients in LUX-Lung 3 and LUX-Lung 6 based on afatinib … 22 and day 43 in patients
remaining on afatinib 40 mg, dose … in combined analyses of LUX-Lung 3 and LUX-Lung 6. Boxes …

… mutations (LUX-Lung 3). In this study, 59.6% and 49.8% of afatinib-treated patients survived
… In the present study, as in the primary analysis, afatinib significantly improved PFS, TTF and …